beta-Thalassemia: all 312 studies
Page 1 of 4. Open to participants first (73), then studies with results posted, then the rest; newest registration first within each.
- Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-ThalassemiaRecruitingNCT07884773Phase 3
- Gene Therapy for Patients With Transfusion-Dependent β-ThalassemiaNot yet recruitingNCT07721480Phase 2
- Transfusion-Related Changes in Oxidative Stress Biomarkers in NeonatesRecruitingNCT07672275
- The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With ThalassemiaNot yet recruitingNCT07660224Not applicable
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsRecruitingNCT07599176Phase 1/2
- Risk Factors Affecting Growth in Thalassemic Children at AUCHNot yet recruitingNCT07509996
- Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm InfantsNot yet recruitingNCT07502781Not applicable
- Evaluation of Micro RNA-155 Expression in Relation to Alloantibody Formation in Transfusion-Dependent PatientsNot yet recruitingNCT07480980
- Open-Label Extension Study to Pioneer Study 6058-SCD-101Enrolling by invitationNCT07401823Phase 2
- Gonadal Function in Thalassemic PatientNot yet recruitingNCT07288762
- Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta ThalassemiaNot yet recruitingNCT07157722Phase 3
- Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia MajorRecruitingNCT07112703Not applicable
- The Effect of Laughter Yoga in Beta Thalassaemia Major Patients: a Randomised Controlled TrialNot yet recruitingNCT06980662Not applicable
- A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaRecruitingNCT06772766Phase 1
- Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemiaRecruitingNCT06734520Not applicable
- A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionEnrolling by invitationNCT06717932
- A Long-term Follow-up Study in Participants Who Received CS-101Enrolling by invitationNCT06685536
- A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-ThalassemiaNot yet recruitingNCT06678165Early Phase 1
- Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene TherapyEnrolling by invitationNCT06664541
- Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.RecruitingNCT06655662Phase 1
- Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesRecruitingNCT06647979Phase 1
- Adherence of Beta Thalssemia Patients to Oral Chelation TherapyRecruitingNCT06568926Not applicable
- FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesRecruitingNCT06539169
- Plasticizer Exposure and Its Consequences on HealthNot yet recruitingNCT06512298
- Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta ThalassemiaRecruitingNCT06490627Phase 2
- A Long-term Follow-up Study in Participants Who Received CS-101RecruitingNCT06479616Not applicable
- Inspiratory Muscle Training in Children With Beta ThalasemiaRecruitingNCT06466304Not applicable
- A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorRecruitingNCT06465550Phase 1
- EKLF Gene Expression in β-thalassemiaNot yet recruitingNCT06440603
- Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia PatientsNot yet recruitingNCT06433570
- Thyroid Function , HbA1c in Relation to Ferritin Level in Adullt Patient e B ThalassemiaNot yet recruitingNCT06377865
- ALS20-101 Lentiviral Gene Therapy for Beta ThalassemiaRecruitingNCT06364774Phase 1/2
- A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301Enrolling by invitationNCT06363760
- CS-101 in Patients With β-thalassemiaEnrolling by invitationNCT06328764Early Phase 1
- Long-term Follow-up Study of BHC001 for TDTRecruitingNCT06314529
- Long-term Follow-up Study of BRL-101 for TDTRecruitingNCT06298630
- Β-Thalassemia Treatment with KL003 Cell InjectionRecruitingNCT06280378Phase 1/2
- A Study of Participants with Β-Thalassemia Treated with Betibeglogene AutotemcelRecruitingNCT06271512
- Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia PatientsRecruitingNCT06219239Not applicable
- Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemiaRecruitingNCT06164821Not applicable
- "Iron Overload and Endocrinological Diseases"RecruitingNCT06137079
- A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemiaRecruitingNCT06073860
- Bone Denisty Change in Children With Beta Thalassemia MajorNot yet recruitingNCT06069089
- Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem CellsRecruitingNCT06041620Not applicable
- Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing FactorsNot yet recruitingNCT06026839
- Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene TherapyRecruitingNCT05991336
- Pumilio1 (PUM1) Expression, Sickle Cell Anemia, β-thalassemia IntermediaNot yet recruitingNCT05883254
- the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-ThalassemiaRecruitingNCT05864170Early Phase 1
- Study of the Role of Genetic Modifiers in HemoglobinopathiesRecruitingNCT05799118
- Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemiaRecruitingNCT05776173Not applicable
- Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemiaRecruitingNCT05773729Not applicable
- A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]RecruitingNCT05762510Early Phase 1
- Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major PatientsRecruitingNCT05745532Early Phase 1
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesRecruitingNCT05635266
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseaseRecruitingNCT05477563Phase 3
- Evaluation of Heart Status in Patients of Beta Thalassemia Using EchocardiogramRecruitingNCT04929574
- Association of Hb F Level With Clinical Severity of Beta ThalassemiaRecruitingNCT04917978
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICRecruitingNCT04528355
- The BENeFiTS Trial in Beta Thalassemia IntermediaEnrolling by invitationNCT04432623Phase 1/2
- Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine SupplementationRecruitingNCT04291352Not applicable
- Thrombophilia In Beta ThalassemiaNot yet recruitingNCT04219449
- A Long-term Follow-up Study in Participants Who Received CTX001Enrolling by invitationNCT04208529Phase 3
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Phase 2
- AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell DepletionRecruitingNCT04099966Phase 2
- Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable
- A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsRecruitingNCT04064060Phase 3
- Collection of Human Biospecimens for Basic and Clinical Research Into Globin VariantsRecruitingNCT03937817
- T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasRecruitingNCT03653338Phase 1/2
- Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral VectorNot yet recruitingNCT03351829Not applicable
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 2
- Study of Panobinostat (LBH589) in Patients With Sickle Cell DiseaseRecruitingNCT01245179Phase 1
- Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and CanadaCompletedNCT05506358Not applicableResults posted
- Pilot Study PBSCT With TCRab Depletion For HemoglobinopathiesCompletedNCT04523376Not applicableResults posted
- A Study of IMR-687 in Subjects With Beta ThalassemiaTerminatedNCT04411082Phase 2Results posted
- Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemiaCompletedNCT04364269Phase 2Results posted
- Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)TerminatedNCT04059406Phase 2Results posted
- Pharmacokinetics of Oral Hydroxyurea SolutionCompletedNCT03763656Phase 1/2Results posted
- Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedNCT03591575Phase 4Results posted
- A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)CompletedNCT03432364Phase 1/2Results posted
- A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-ThalassemiaCompletedNCT03207009Phase 3Results posted
- A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 GenotypeCompletedNCT02906202Phase 3Results posted
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) ThalassemiaCompletedNCT02604433Phase 3Results posted
- HSCT For Patients With High Risk Hemoglobinopathies Using Reduced IntensityCompletedNCT02435901Phase 1/2Results posted
- Decision Aid for Therapeutic Options In Sickle Cell DiseaseCompletedNCT02326597Not applicableResults posted
- Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)CompletedNCT02268409Phase 2Results posted
- A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell DiseaseCompletedNCT02151526Phase 1/2Results posted
- Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.CompletedNCT02049450Phase 2Results posted
- A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major ParticipantsCompletedNCT01745120Phase 1/2Results posted
- Combination Deferasirox and Deferiprone for Severe Iron Overload in ThalassemiaCompletedNCT01709032Phase 1/2Results posted
- Post Hematopoietic Stem Cell TransplantationCompletedNCT01610297Phase 4Results posted
- Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.TerminatedNCT01571635Phase 2Results posted
- Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadTerminatedNCT01459718Phase 2Results posted
- Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron OverloadTerminatedNCT01363908Phase 2Results posted
- Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron OverloadCompletedNCT01186419Phase 2Results posted
- Pilot Study for Patients With Poor Response to DeferasiroxCompletedNCT00749515Phase 4Results posted
- Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia IntermediaCompletedNCT00661726Phase 2Results posted
- Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia MajorCompletedNCT00658385Not applicableResults posted
- Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedNCT00447694Phase 2Results posted